Clinical Report: Assessment of HBV and HCV Seroprevalence in Earthquake Survivors

Overview

This study evaluates the seroprevalence of HBV and HCV infections among earthquake survivors in Southeastern Türkiye using rapid point-of-care tests. The findings highlight the importance of screening in disaster-affected populations to prevent further transmission of these viral infections.

Background

The recent earthquakes in Türkiye have led to significant displacement and disruption of healthcare services, increasing the risk of viral infections such as HBV and HCV. With a notable prevalence of HBV in the Southeastern Anatolia Region, understanding the seroprevalence in this vulnerable population is crucial for public health interventions. Rapid point-of-care testing offers a feasible solution for screening in emergency settings.

Data Highlights

Key Findings

• The seroprevalence of HBV in Türkiye is reported at 4%, with the Southeastern Anatolia Region having rates as high as 7.3%.
• HBV vaccination programs have significantly reduced acute HBV cases in Türkiye.
• The seroprevalence of HCV infection in Türkiye is low, ranging from 0.5% to 1%, but higher in older age groups.
• Rapid diagnostic tests (RDT) are effective for screening in populations with limited access to standard laboratory services.
• Approximately 40% of people who inject drugs in Türkiye are anti-HCV positive, indicating a high-risk group for HCV.

Clinical Implications

Healthcare providers should prioritize HBV and HCV screening in disaster-affected populations to mitigate the risk of viral transmission. Implementing rapid point-of-care testing can facilitate timely diagnosis and linkage to care, especially in temporary shelters and communal living areas.

Conclusion

The assessment of HBV and HCV seroprevalence in earthquake survivors underscores the need for targeted public health strategies in crisis situations. Rapid testing can play a vital role in managing and preventing viral infections in vulnerable populations.

References

1. Open Forum Infectious Diseases, 2021 -- Seroprevalence of Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Among People Who Use Drugs in Turkey
2. Open Forum Infectious Diseases, 2021 -- Utilizing Point-of-Care Testing for Hepatitis B Core Antigen in Risk Assessment for Treatment Eligibility: Insights from Kenya
3. Infection, 2022 -- Hepatitis D Virus Infection Among a Large Immigrant Population in Southern Italy: Findings from a Multicenter Prospective Study
4. Infection, 2025 -- Implementation and Outcomes of a Comprehensive Screening Initiative for HIV, HBV, and HCV in an Emergency Department Setting
5. AASLD/IDSA Practice Guideline Update on Treatment of Chronic Hepatitis B, 2025
6. WHO Guidance on Communicable Diseases Following Natural Disasters
7. AASLD/IDSA Practice Guideline Update on Treatment of Chronic Hepatitis B
8. Point-of-Care Hepatitis C Testing in a Tribal Setting - PMC